However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...
(Editor’s note: This is the first in an occasional series of stories commemorating the 20th anniversary of the Marshalltown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback